In particular, CRISPR/Cas technology has led to significant scientific advances in the study and treatment of KRAS-driven cancers, broadening our understanding of mechanistic insights into KRAS-driven tumor initiation, progression, and resistance to therapy, as well as synthetic lethal interactions with mutant KRAS. The gene discussed is KRAS; the disease is cancer.